<DOC>
	<DOCNO>NCT02864615</DOCNO>
	<brief_summary>Aim phase 1b study evaluate safety preliminary efficacy stereotactic body radiation therapy patient metastatic renal cell carcinoma treat VEGFR , mTOR immune checkpoint inhibitor .</brief_summary>
	<brief_title>Safety Preliminary Efficacy SBRT Patients With Metastatic RCC Treated With Targeted IO Therapy</brief_title>
	<detailed_description>This prospective phase 1b study . Patients metastatic RCC receiving target IO therapy ( VEGFR inhibitor mTOR inhibitor checkpoint inhibitor approve treatment line standard therapeutic regimen ) stable diseaseor durable partial response least 4 month , enrol study . The initial examination include CT contrast , select measure 2 metastatic site , stable least 4 month 6 month target therapy ( increase decrease size course target therapy exceed 10 % ) . Metastases locate one organ . Allowed location metastasis : lung , liver , lymph node , contralateral kidney , adrenal gland . Size select metastasis less 5 mm 4 cm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>1. clear cell renal cell carcinoma 2. confirm distant metastasis 3. previous nephrectomy 4. stable disease durable partial response recommend targeted IO therapy 5. age : &gt; 18 year 6. sign inform consent 1. unability select first second metastasis 2. history serious cardiac arrhythmia , congestive heart failure , angina pectoris , severe cardiovascular disease ( i.e. , New York Heart Association class III IV ) 3. malignancy 4. grade 3 4 toxicity target therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>metastasis</keyword>
	<keyword>stereotactic body radiation therapy</keyword>
	<keyword>targted therapy</keyword>
	<keyword>immune checkpoint inhibitor</keyword>
</DOC>